[Experiences with bencyclane in peripheral disorders of arterial blood supply].
D000328:Adult; D000368:Aged; D001158:Arteries; D001162:Arteriosclerosis Obliterans / Q000188:drug therapy; D002560:Cerebrovascular Circulation; D003508:Cycloheptanes / Q000494:pharmacology / Q000627:therapeutic use*; D003925:Diabetic Angiopathies / Q000188:drug therapy; D005260:Female; D005650:Fumarates / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007866:Leg / Q000098:blood supply*; D008297:Male; D008875:Middle Aged; D010276:Parasympatholytics / Q000494:pharmacology / Q000627:therapeutic use*; D011437:Propylamines / Q000494:pharmacology / Q000627:therapeutic use*; D012039:Regional Blood Flow; D013035:Spasm / Q000188:drug therapy; D013919:Thromboangiitis Obliterans / Q000188:drug therapy; D013927:Thrombosis / Q000188:drug therapy; D014652:Vascular Diseases / Q000188:drug therapy*; D014665:Vasodilator Agents / Q000627:therapeutic use
D003508:Cycloheptanes; D005650:Fumarates; D010276:Parasympatholytics; D011437:Propylamines; D014665:Vasodilator Agents
Erfahrungen mit Bencyclan bei peripheren Störungen der arteriellen Blutversorgung.